SecBot SecBot
8-K ·Filed Aug 11, 2026

TARA

Protara Therapeutics, Inc.
NEUTRAL
Impact 4/10
Horizonmonths Processed3mo ago SEC0001213900-26-087506
8-K Item 2.02: Earnings release
Actionable Insight • Neutral

Monitor Q4 2026 for enrollment completion in ADVANCED-2 and interim THRIVE-3 data, which are the next major catalysts. The ADVANCED-3 redesign is a strategic shift that may delay a registrational path in BCG-Naive patients, increasing uncertainty around the NMIBC program's timeline.

DirectionNeutral
Confidencehigh
Horizonmonths

Price Chart

Loading chart...

Executive Summary

Protara Therapeutics reported Q2 2026 results with a net loss of $21.7M ($0.36/share), widening from a $15.0M loss in Q2 2025, driven by increased R&D spending on clinical trials. The company highlighted key pipeline milestones: expects to complete enrollment in the BCG-Unresponsive cohort of the ADVANCED-2 trial in Q4 2026, is redesigning the ADVANCED-3 trial as an exploratory study, and remains on track to report interim THRIVE-3 results in Q4 2026. Cash of $161.9M is expected to fund operations into 2028, but the widening losses and trial redesign signal a longer path to commercialization without near-term revenue catalysts.

Key Financial Metrics

EPS
−$0.36
est −$0.33 · -9.1%
Rating
miss

Key Facts

  • Net loss for Q2 2026 was $21.7 million, or $0.36 per share, compared to a net loss of $15.0 million, or $0.35 per share, in Q2 2025.
  • Cash, cash equivalents and investments totaled $161.9 million as of June 30, 2026, expected to support operations into 2028.
  • The ADVANCED-3 trial is being redesigned as a multi-cohort, open-label, exploratory trial to study TARA-002 in a broader NMIBC patient population.
  • Company expects to complete enrollment of the BCG-Unresponsive registrational cohort of the ADVANCED-2 trial in Q4 2026.
  • Interim results from the THRIVE-3 registrational trial of IV Choline Chloride are expected in Q4 2026.
  • TARA-002 demonstrated clinical success in 83% (10/12) of participants that completed treatment in the STARBORN-1 trial for LMs.

Financial Impact

Net loss widened by $6.7M YoY to $21.7M in Q2 2026; R&D expenses increased by $6.2M to $17.0M.

net lossR&D expensescash position

Risk Factors

  • Widening net losses with no near-term revenue prospects increase cash burn rate.
  • Redesign of ADVANCED-3 trial introduces uncertainty in the NMIBC development timeline and regulatory path.
  • Clinical trial enrollment and data readout risks across all pipeline programs (NMIBC, LMs, IV Choline Chloride).

Market Snapshot

Exchange
Nasdaq
Sector
Biological Products, (No Diagnostic Substances)
Analyst Consensus
93% bullish (14 analysts)

Investment Themes

Documents Analyzed

This report is based on 6 SEC documents filed with EDGAR.

DocumentAccession Number
8-K Filing (Primary)0001213900-26-087506
Document: ea0299236-8k_protara.htm0001213900-26-087506
Document: 0001213900-26-087506-index-headers.html0001213900-26-087506
Document: 0001213900-26-087506-index.html0001213900-26-087506
Document: 0001213900-26-087506.txt0001213900-26-087506
8-K Data (Synthetic)0001213900-26-087506

Track record

13 reports on TARA

Performance horizon

1 of 3 bullish or bearish reports moved the stock their way by T+60. Best: +17.50% at T+60 after the May 26, 2026 report. 1 of 3 went positive at some point.

Filters
  1. Nov 16, 2026today SC 13G/A Bearish 4/10 Entry $2.52 Now $2.38 +5.56% settles Feb 12
  2. Nov 6, 202610d ago 8-K Neutral 4/10 No price data
  3. Nov 6, 202610d ago Press Release Neutral 4/10 Entry $2.30 Now $2.38 +3.48% settles Feb 4
  4. Oct 15, 20264w ago Press Release Neutral 3/10 Entry $2.40 Now $2.38 −0.83% settles Jan 12
  5. Aug 11, 202613w ago 8-K Neutral 4/10 Viewing No price data
  6. Aug 11, 202613w ago Press Release Neutral 4/10 Entry $3.91 to $2.35 Now $2.38 −39.13% ▼ −39.90% −39.41% vs SPY
  7. Jun 29, 202620w ago 8-K Neutral 2/10 Entry $3.82 to $3.54 Now $2.38 −37.70% ▼ −7.33% −10.15% vs SPY
  8. May 26, 202625w ago EFFECT Bearish 5/10 Entry $4.80 to $3.96 Now $2.38 +50.42% ▲ +17.50% +20.22% vs SPY
  9. May 15, 202626w ago Press Release Bullish 7/10 Entry $5.10 to $3.91 Now $2.38 −53.33% ▼ −23.33% −27.85% vs SPY
  10. May 13, 202626w ago 8-K Neutral 4/10 No price data
Showing 10 of 13

US Market Status

Market Closed · Opens in 6h 31m

Subscribe to SecBot

Get Real-Time SEC Filing Intelligence

Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.

Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers
Report published Aug 11, 2026